Literature DB >> 26905915

Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor.

Neel Dixit1, Adam Castano, Mary Jane Farr, Rebecca Traub, Suzanne Lentzsch, Robert S Brown, Mathew S Maurer, Thomas H Brannagan.   

Abstract

Domino liver transplantation, in which the liver of a patient with transthyretin-mediated amyloidosis is transplanted into another patient, has been an established procedure performed at several centers across the world. The risk of developing systemic amyloidosis in transthyretin-mediated amyloidosis liver transplant recipients is a topic of ongoing investigation. We report a case of rapidly progressive transthyretin amyloidosis in a patient who received a liver from a donor with a rare Ser23Asn mutation. We advise exercising caution when considering domino liver transplantation in patients with this particular mutation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26905915     DOI: 10.1097/CND.0000000000000110

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  3 in total

Review 1.  Iatrogenic amyloid polyneuropathy after domino liver transplantation.

Authors:  Diana Mnatsakanova; Saša A Živković
Journal:  World J Hepatol       Date:  2017-01-28

2.  Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy.

Authors:  Velina Nedkova-Hristova; Carmen Baliellas; José González-Costello; Laura Lladó; Emma González-Vilatarsana; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Transpl Int       Date:  2022-04-13       Impact factor: 3.842

Review 3.  Rare variant (p.Ser43Asn) of familial transthyretin amyloidosis associated with isolated cardiac phenotype: A case series with literature review.

Authors:  Maria Papathanasiou; Alexander Carpinteiro; David Kersting; Aiste-Monika Jakstaite; Tim Hagenacker; Thomas-Wilfried Schlosser; Christoph Rischpler; Tienush Rassaf; Peter Luedike
Journal:  Mol Genet Genomic Med       Date:  2020-12-20       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.